Visual outcome, local tumour control, and eye preservation after ¹⁰⁶Ru/Rh brachytherapy for choroidal melanoma

References

• Isager P, Østerlind A, Engholm G, Heegaard S, Lindegaard J, Overgaard J, et al. Malignant melanoma in the ocular region in Denmark 1943–97. Incidence and validation study. Ophthal Epidemiol 2005; 12: 223–32
   PubMed Web of Science ®Google Scholar
• The Collaborative Ocular Melanoma Study Group. The COMS randomized trial of iodine 125 brachytherapy for choroidal melanoma, III: Initial mortality findings. COMS Report No. 18. Arch Ophthalmol 2001; 119: 969–82
   PubMedGoogle Scholar
• Augsburger JJ, Schneider S, Freire J, Brady LW. Survival following enucleation versus plaque radiotherapy in statistically matched subgroups of patients with choroidal melanomas: Results in patients treated between 1980 and 1987. Graefes Arch Clin Exp Ophthalmol 1999; 237: 558–67
   PubMed Web of Science ®Google Scholar
• Courdi A, Caujolle JP, Grange JD, Diallo-Rosier L, Sahel J, Bacin F, et al. Results of proton therapy of uveal melanomas treated in Nice. Int J Radiat Oncol Biol Phys 1999; 45: 5–11
   PubMed Web of Science ®Google Scholar
• Seddon JM, Gragoudas ES, Egan KM, Glynn RJ, Howard S, Fante RG, et al. Relative survival rates after alternative therapies for uveal melanoma. Ophthalmology 1990; 97: 769–77
   PubMed Web of Science ®Google Scholar
• Castro JR, Char DH, Petti PL, Daftari IK, Quivey JM, Singh RP, et al. 15 years experience with helium ion radiotherapy for uveal melanoma. Int J Radiat Oncol Biol Phys 1997; 39: 989–96
   PubMed Web of Science ®Google Scholar
• Foulds WS, Damato BE, Burton RL. Local resection versus enucleation in the management of choroidal melanoma. Eye 1987; 1(Pt 6)676–9
   PubMed Web of Science ®Google Scholar
• Shields JA, Shields CL, Shah P, DePotter P. Current alternatives in the management of posterior uvea melanomas. Trans Pa Acad Ophthalmol Otolaryngol 1990; 42: 938–44
   PubMedGoogle Scholar
• Shields JA, Shields CL. Current management of posterior uveal melanoma. Mayo Clin Proc 1993; 68: 1196–200
   PubMed Web of Science ®Google Scholar
• Damato BE. An approach to the management of patients with uveal melanoma. Eye 1993; 7(Pt 3)388–97
   PubMed Web of Science ®Google Scholar
• Union Internationale Contre le Cancer. 1997. TNM Classification of Malignant Tumours 5th edition.
   Google Scholar
• The Collaborative Ocular Melanoma Study. Histopathologic characteristics of uveal melanomas in eyes enucleated from the Collaborative Ocular Melanoma Study. COMS report no. 6. Am J Ophthalmol 1998;125:745–66.
   PubMed Web of Science ®Google Scholar
• Seregard S, af Trampe E, Lax I, Kock E, Lundell G. Results following episcleral ruthenium plaque radiotherapy for posterior uveal melanoma. The Swedish experience. Acta Ophthalmol Scand 1997; 75: 11–6
   PubMedGoogle Scholar
• Collaborative Ocular Melanoma Study. Collaborative Ocular Melanoma Study (COMS) randomized trial of I-125 brachytherapy for medium choroidal melanoma. I. Visual acuity after 3 years COMS report no. 16. Ophthalmology 2001; 108: 348–66
   PubMed Web of Science ®Google Scholar
• Bergman L, Nilsson B, Lundell G, Lundell M, Seregard S. Ruthenium brachytherapy for uveal melanoma, 1979–2003: Survival and functional outcomes in the Swedish population. Ophthalmology 2005; 112: 834–40
   PubMed Web of Science ®Google Scholar
• Shields CL, Shields JA, Cater J, Gündüz K, Miyamoto C, Micaily B, et al. Plaque radiotherapy for uveal melanoma: Long-term visual outcome in 1106 consecutive patients. Arch Ophthalmol 2000; 118: 1219–28
   PubMedGoogle Scholar
• Shields CL, Naseripour M, Cater J, Shields JA, Demirci H, Youseff A, et al. Plaque radiotherapy for large posterior uveal melanomas (>or = 8-mm thick) in 354 consecutive patients. Ophthalmology 2002; 109: 1838–49
   PubMed Web of Science ®Google Scholar
• Lommatzsch PK, Werschnik C, Schuster E. Long-term follow-up of Ru-106/Rh-106 brachytherapy for posterior uveal melanoma. Graefes Arch Clin Exp Ophthalmol 2000; 238: 129–37
   PubMed Web of Science ®Google Scholar
• Bornfeld N, Chauvel P, Sauerwein W, Friedrichs W, Tiburtius T, Wessing A, et al. Metastatic disease, eye retention and visual function in conservative treatment of uveal melanoma. Front Radiat Ther Oncol 1997; 30: 97–110
   PubMedGoogle Scholar
• Wilson MW, Hungerford JL. Comparison of episcleral plaque and proton beam radiation therapy for the treatment of choroidal melanoma. Ophthalmology 1999; 106: 1579–87
   PubMed Web of Science ®Google Scholar
• Lommatzsch PK, Lommatzsch R. Treatment of juxtapapillary melanomas. Br J Ophthalmol 1991; 75: 715–7
   PubMed Web of Science ®Google Scholar
• Damato BE, Paul J, Foulds WS. Predictive factors of visual outcome after local resection of choroidal melanoma. Br J Ophthalmol 1993; 77: 616–23
   PubMed Web of Science ®Google Scholar
• Damato BE, Paul J, Foulds WS. Risk factors for residual and recurrent uveal melanoma after trans-scleral local resection. Br J Ophthalmol 1996; 80: 102–8
   PubMed Web of Science ®Google Scholar
• Gündüz K, Shields CL, Shields JA, Cater J, Freire JE, Brady LW. Radiation retinopathy following plaque radiotherapy for posterior uveal melanoma. Arch Ophthalmol 1999; 117: 609–14
   PubMedGoogle Scholar
• Fontanesi J, Meyer D, Xu S, Tai D. Treatment of choroidal melanoma with I-125 plaque. Int J Radiat Oncol Biol Phys 1993; 26: 619–23
   PubMed Web of Science ®Google Scholar
• Lommatzsch PK. Results after beta-irradiation (106Ru/106Rh) of choroidal melanomas: 20 years' experience. Br J Ophthalmol 1986; 70: 844–51
   PubMed Web of Science ®Google Scholar
• Summanen P, Immonen I, Kivela T, Tommila P, Heikkonen J, Tarkkanen A. Radiation related complications after ruthenium plaque radiotherapy of uveal melanoma. Br J Ophthalmol 1996; 80: 732–9
   PubMed Web of Science ®Google Scholar
• Jones R, Gore E, Mieler W, Murray K, Gillin M, Albano K, et al. Posttreatment visual acuity in patients treated with episcleral plaque therapy for choroidal melanomas: Dose and dose rate effects. Int J Radiat Oncol Biol Phys 2002; 52: 989–95
   PubMed Web of Science ®Google Scholar
• De Potter P, Shields CL, Shields JA, Cater JR, Brady LW. Plaque radiotherapy for juxtapapillary choroidal melanoma. Visual acuity and survival outcome. Arch Ophthalmol 1996; 114: 1357–65
   PubMedGoogle Scholar
• Lommatzsch PK, Alberti W, Lommatzsch R, Rohrwacher F. Radiation effects on the optic nerve observed after brachytherapy of choroidal melanomas with 106Ru/106Rh plaques. Graefes Arch Clin Exp Ophthalmol 1994; 232: 482–7
   PubMed Web of Science ®Google Scholar
• Gündüz K, Shields CL, Shields JA, Cater J, Freire JE, Brady LW. Radiation complications and tumor control after plaque radiotherapy of choroidal melanoma with macular involvement. Am J Ophthalmol 1999; 127: 579–89
   PubMed Web of Science ®Google Scholar
• Gragoudas ES, Li W, Lane AM, Munzenrider J, Egan KM. Risk factors for radiation maculopathy and papillopathy after intraocular irradiation. Ophthalmology 1999; 106: 1571–7
   PubMed Web of Science ®Google Scholar
• Gündüz K, Shields CL, Shields JA, Cater J, Freire JE, Brady LW. Plaque radiotherapy of uveal melanoma with predominant ciliary body involvement. Arch Ophthalmol 1999; 117: 170–7
   PubMedGoogle Scholar
• Char DH, Kroll S, Quivey JM, Castro J. Long term visual outcome of radiated uveal melanomas in eyes eligible for randomisation to enucleation versus brachytherapy. Br J Ophthalmol 1996; 80: 117–24
   PubMed Web of Science ®Google Scholar
• Summanen P, Immonen I, Kivela T, Tommila P, Heikkonen J, Tarkkanen A. Visual outcome of eyes with malignant melanoma of the uvea after ruthenium plaque radiotherapy. Ophthalmic Surgery and Lasers 1995; 26: 449–60
   PubMedGoogle Scholar
• Summanen P, Immonen I, Heikkonen J, Tommila P, Laatikainen L, Tarkkanen A. Survival of patients and metastatic and local recurrent tumor growth in malignant melanoma of the uvea after ruthenium plaque radiotherapy. Ophthalmic Surgery 1993; 24: 82–90
   PubMedGoogle Scholar
• Rouberol F, Roy P, Kodjikian L, Gerard JP, Jean-Louis B, Grange JD. Survival, anatomic, and functional long-term results in choroidal and ciliary body melanoma after ruthenium brachytherapy (15 years' experience with beta-rays). Am J Ophthalmol 2004; 137: 893–900
   PubMed Web of Science ®Google Scholar
• Damato, B, Patel, I, Campbell, IR, Mayles, HM, Errington, RD. Local tumor control after (106)Ru brachytherapy of choroidal melanoma. Int J Radiat Oncol Biol Phys 2005.
   Google Scholar
• Collaborative Ocular Melanoma Study Group. The COMS randomized trial of iodine 125 brachytherapy for choroidal melanoma: IV. Local treatment failure and enucleation in the first 5 years after brachytherapy. COMS report no. 19. Ophthalmology 2002; 109: 2197–206
   PubMed Web of Science ®Google Scholar
• Kleineidam M, Guthoff R, Bentzen SM. Rates of local control, metastasis, and overall survival in patients with posterior uveal melanomas treated with ruthenium-106 plaques. Radiother Oncol 1993; 28: 148–56
   PubMed Web of Science ®Google Scholar
• Muller RP, Busse H, Potter R, Kroll P, Haverkamp U. Results of high dose 106-ruthenium irradiation of choroidal melanomas. Int J Radiat Oncol Biol Phys 1986; 12: 1749–55
   PubMed Web of Science ®Google Scholar
• Tjho-Heslinga RE, Davelaar J, Kemme HM, de Vroome H, Oosterhuis JA, Bleeker JC, et al. Results of ruthenium irradiation of uveal melanomas: The Dutch experience. Radiother Oncol 1999; 53: 133–7
   PubMed Web of Science ®Google Scholar
• Quivey JM, Augsburger J, Snelling L, Brady LW. 125I plaque therapy for uveal melanoma. Analysis of the impact of time and dose factors on local control. Cancer 1996; 77: 2356–62
   PubMed Web of Science ®Google Scholar
• Char DH, Quivey JM, Castro JR, Kroll S, Phillips T. Helium ions versus iodine 125 brachytherapy in the management of uveal melanoma. A prospective, randomized, dynamically balanced trial. Ophthalmology 1993; 100: 1547–54
   PubMed Web of Science ®Google Scholar
• Char DH, Kroll S, Phillips TL, Quivey JM. Late radiation failures after iodine 125 brachytherapy for uveal melanoma compared with charged-particle (proton or helium ion) therapy. Ophthalmology 2002; 109: 1850–4
   PubMed Web of Science ®Google Scholar
• Munzenrider JE, Gragoudas ES, Seddon JM, Sisterson J, McNulty P, Birnbaum S, et al. Conservative treatment of uveal melanoma: Probability of eye retention after proton treatment. Int J Radiat Oncol Biol Phys 1988; 15: 553–8
   PubMed Web of Science ®Google Scholar
• Gragoudas E, Li W, Goitein M, Lane AM, Munzenrider JE, Egan KM. Evidence-based estimates of outcome in patients irradiated for intraocular melanoma. Arch Ophthalmol 2002; 120: 1665–71
   PubMed Web of Science ®Google Scholar
• Gragoudas ES, Egan KM, Walsh SM, Regan S, Munzenrider JE, Taratuta V. Lens changes after proton beam irradiation for uveal melanoma. Am J Ophthalmol 1995; 119: 157–64
   PubMed Web of Science ®Google Scholar
• Shields CL, Shields JA, Perez N, Singh AD, Cater J. Primary transpupillary thermotherapy for small choroidal melanoma in 256 consecutive cases: Outcomes and limitations. Ophthalmology 2002; 109: 225–34
   PubMed Web of Science ®Google Scholar
• Seregard S, Landau I. Transpupillary thermotherapy as an adjunct to ruthenium plaque radiotherapy for choroidal melanoma. Acta Ophthalmol Scand 2001; 79: 19–22
   PubMedGoogle Scholar
• Shields CL, Cater J, Shields JA, Chao A, Krema H, Materin M, et al. Combined plaque radiotherapy and transpupillary thermotherapy for choroidal melanoma: Tumor control and treatment complications in 270 consecutive patients. Arch Ophthalmol 2002; 120: 933–40
   PubMedGoogle Scholar
• Journee-de Korver JG, Keunen JE. Thermotherapy in the management of choroidal melanoma. Prog Retin Eye Res 2002; 21: 303–17
   PubMed Web of Science ®Google Scholar
• Dieckmann K, Georg D, Zehetmayer M, Bogner J, Georgopoulos M, Potter R. LINAC based stereotactic radiotherapy of uveal melanoma: 4 years clinical experience. Radiother Oncol 2003; 67: 199–206
   PubMed Web of Science ®Google Scholar
• Shields CL, Shields JA, Karlsson U, Markoe AM, Brady LW. Reasons for enucleation after plaque radiotherapy for posterior uveal melanoma. Clinical findings. Ophthalmology 1989; 96: 919–23
   PubMed Web of Science ®Google Scholar